JACC. Case reports · 2025
Cardiotoxicity Conundrum: Distinguishing Immune Checkpoint Inhibitor Myocarditis From Fluorouracil Cardiotoxicity in Concurrent Therapy.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hu Vivian, Naidu Ishan, Singh Nausheen, Akinmolayemi Oludamilola, Sahni Gagan
Аннотация
BACKGROUND: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment over the past decade; however, it is crucial to recognize their rare but clinically significant cardiotoxicities. These agents are often combined with other chemotherapeutics carrying distinct cardiotoxic profiles.
CASE SUMMARY: A 37-year-old man presented with cardiogenic shock shortly after initiating ICI and fluorouracil (5FU) therapy. He was treated concurrently for suspected ICI myocarditis and 5FU cardiotoxicity with rapid improvement. Given higher suspicion for 5FU as the culprit, he was rechallenged successfully with nivolumab.
DISCUSSION: Distinguishing between overlapping cardiotoxicities and establishing causality can be challenging in patients receiving combination therapy. Diagnostic tests alone may be insufficient to confirm a diagnosis and should be complemented by a thorough assessment of risk factors and clinical presentation.
TAKE-HOME MESSAGE: This case highlights the importance of prompt and accurate identification of a causative agent for cardiotoxicity with consequential impact on future therapeutics and cancer prognosis.
CASE SUMMARY: A 37-year-old man presented with cardiogenic shock shortly after initiating ICI and fluorouracil (5FU) therapy. He was treated concurrently for suspected ICI myocarditis and 5FU cardiotoxicity with rapid improvement. Given higher suspicion for 5FU as the culprit, he was rechallenged successfully with nivolumab.
DISCUSSION: Distinguishing between overlapping cardiotoxicities and establishing causality can be challenging in patients receiving combination therapy. Diagnostic tests alone may be insufficient to confirm a diagnosis and should be complemented by a thorough assessment of risk factors and clinical presentation.
TAKE-HOME MESSAGE: This case highlights the importance of prompt and accurate identification of a causative agent for cardiotoxicity with consequential impact on future therapeutics and cancer prognosis.